THE SHORT ANSWER
What can we learn from the phase 2 study?
The 2023 placebo-controlled trial reported weight reduction with retatrutide in adults with overweight or obesity.
The important limitation
This is a historical study overview, not a current evidence inventory. Later results and regulatory status require a separate review.
ONE STEP DEEPER
Open the evidence.
See how the study was designed and where its findings apply.
Overview first. Grade pending.
This sample demonstrates a useful overview without a completed grade. Pending review is not evidence of ineffectiveness or an absence of human research.
KEEP THE SCOPE IN VIEW
Safety & regulatory context.
The trial reported gastrointestinal adverse events and dose-related increases in heart rate. This paper cannot settle longer-term safety.
No approval status is inferred from a compound name. Jurisdiction, formulation, indication, and a dated primary source are needed for a regulatory entry.
How to read safety & statusCHECK THE ORIGINAL RESEARCH
Sources you can inspect.
- 01
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM et al. · New England Journal of Medicine · 2023
A VISIBLE RECORD
What changed here?
A direct link to the phase 2 paper.
An illustrative source addition; no new grade or scientific conclusion is implied.
Open the change record